Firm at a glance
Astorg is a platform private equity firm with offices in London, Paris, New York, Milan, Frankfurt, and Luxembourg, per its own website [S1]. The firm reports approximately €24 billion in assets under management and is currently investing from its 8th generation buyout fund [S1].
What they buy
Based on publicly disclosed portfolio activity, Astorg acquires platform businesses across healthcare, industrials, business services, and technology sectors [S1]. Recent platform investments include healthcare companies IPL (2026) and Nexpring Health (2024), industrial businesses Solabia and LBA (Lebronze alloys) (both 2025), business services firm Attikon (2025), and technology company Redslim (2025) [S1]. The firm appears to pursue mid-market and larger platforms with international growth potential, as evidenced by its multi-country office footprint and portfolio composition.
Portfolio
Healthcare
IPL (platform, acquired 2026) [S1]
Nexpring Health (platform, acquired 2024) [S1]
Industrials
Solabia (platform, acquired 2025) [S1]
LBA (Lebronze alloys) (platform, acquired 2025) [S1]
Business Services
Attikon (platform, acquired 2025) [S1]
Tech
Redslim (platform, acquired 2025) [S1]
Recent activity (last 24 months)
* June 2026: CordenPharma acquires AmbioPharm (add-on) [S1]
* June 2026: Steliau to acquire Acal BFI (add-on) [S1]
* April 2026: Acquisition of Global Microbiology Business from Thermo Fisher Scientific [S1]
* 2026: Acquisition of IPL [S1]
* 2025: Acquisition of Solabia [S1]
* 2025: Acquisition of Attikon [S1]
* 2025: Acquisition of Redslim [S1]
* 2025: Acquisition of LBA (Lebronze alloys) [S1]
* November 2024: Exit of Anaqua to Nordic Capital [S2]
How this firm fits a seller
Astorg appears suited for owner-operators seeking a buyer with substantial capital resources and international reach, given its approximately €24 billion in assets under management and six-office presence across Europe and North America [S1]. The firm’s recent activity demonstrates both platform acquisition capability and add-on execution, with two add-on transactions completed in mid-2026 alone [S1]. For sellers in healthcare, industrials, business services, or technology sectors, Astorg’s documented investment history suggests active interest in these verticals. The November 2024 exit of Anaqua indicates the firm does complete realizations, providing a data point for sellers evaluating exit track record [S2].
Sources
[S1] https://astorg.com (as of 2026-06-04)
[S2] https://www.lw.com/en/news/2024/11/latham-represents-astorg-on-sale-of-anaqua-to-nordic-capital (as of 2024-11-18)
Frequently asked questions
Does Astorg buy healthcare businesses?
Yes, healthcare represents one of Astorg’s observed investment sectors [S1]. The firm acquired healthcare platform IPL in 2026 and Nexpring Health in 2024, and completed an add-on acquisition of the Global Microbiology Business from Thermo Fisher Scientific in April 2026 [S1].
What companies has Astorg acquired recently?
Recent platform acquisitions include IPL in healthcare (2026), Solabia and LBA (Lebronze alloys) in industrials (both 2025), Attikon in business services (2025), and Redslim in technology (2025) [S1]. The firm also facilitated add-on acquisitions including CordenPharma’s purchase of AmbioPharm in June 2026 [S1].
Where is Astorg based and how big is the firm?
Astorg maintains offices in London, Paris, New York, Milan, Frankfurt, and Luxembourg [S1]. The firm reports approximately €24 billion in assets under management and is currently investing from its 8th generation buyout fund as of mid-2026 [S1].
Is Astorg still actively acquiring?
Yes, Astorg appears actively acquiring based on recent transaction activity. The firm completed platform acquisitions in 2025 and 2026, and facilitated two add-on transactions as recently as June 2026 [S1].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.